Covidien (COV) Q3 2012 Earnings Call July 26, 2012 8:30 am ET Executives Coleman N. Lannum - Vice President of Investor Relations Jose E. Almeida - Chairman of the Board, Chief Executive Officer and President Charles J. Dockendorff - Chief Financial Officer and Executive Vice President Analysts David H. Roman - Goldman Sachs Group Inc., Research Division David R. Lewis - Morgan Stanley, Research Division Michael N. Weinstein - JP Morgan Chase & Co, Research Division Robert A. Hopkins - BofA Merrill Lynch, Research Division Matthew J. Dodds - Citigroup Inc, Research Division Thomas J. Gunderson - Piper Jaffray Companies, Research Division Joanne K. Wuensch - BMO Capital Markets U.S. Matthew O'Brien - William Blair & Company L.L.C., Research Division Matthew Taylor - Barclays Capital, Research Division Kristen M. Stewart - Deutsche Bank AG, Research Division Lawrence S. Keusch - Raymond James & Associates, Inc., Research Division Anthony Petrone - Jefferies & Company, Inc., Research Division Jonathan J. Palmer - Credit Agricole Securities (USA) Inc., Research Division PresentationOperator
Good day, ladies and gentlemen, and welcome to the Q3 2012 Covidien plc Earnings Conference Call. My name is Clinton, and I'll be your operator for today. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. And now, I'd like to turn the call over to Cole Lannum, Vice President of Investor Relations. Please proceed, sir. Coleman N. Lannum Thanks, Clinton, and good morning, everyone. With me today are Joe Almeida, Covidien's Chairman, President and CEO; and Chuck Dockendorff, our Chief Financial Officer.
Ikaria, which focuses on therapies for critically ill infants, is privately owned by a group led by Madison Dearborn Partners. Buyer Mallinckrodt specializes in diagnostic radiology and pain management.